Grifols, ES0171996087

Grifols stock costs EUR 10.13 as first-half revenue rose 2.60 percent

Published on 10/16/2026 at 10:14 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

First-half profit rose 28.70 percent to EUR 227 million on July 28, 2026. Grifols stock costs EUR 10.13 on October 16, 2026.

First-half performance and analyst view

First-half revenue reached EUR 3.574 billion on July 28, 2026, up 2.60 percent at constant currency.
Net profit rose 28.70 percent to EUR 227 million in the first half of 2026.
Grifols stock trades at EUR 10.13 at 10:05 a.m. CEST at Lang & Schwarz on October 16, 2026.
Wall Street Zen cut its rating from Buy to Hold on October 10, 2026.

Flatlay mit Aktienzertifikat, ISIN-Karte und medizinischen Laborutensilien — Flatlay-Arrangement mit Aktienzertifikat und ISIN-Karte symbolisiert die Investition in Grifols S.A. ES0171996087 im Biotech-Bereich, Illustration mit AI erstellt.

Grifols stock (ISIN ES0171996087) was trading at EUR 10.13 at Lang & Schwarz on October 16, 2026, at 10:05 a.m. CEST. The company reported first-half revenue of EUR 3.574 billion, up 2.60 percent at constant currency, in a release dated July 28, 2026, according to Grifols.

Profit growth leads the picture

The latest reported figures show stronger profitability alongside moderate sales growth. Net profit rose 28.70 percent year over year to EUR 227 million in the first half of 2026, while adjusted EBITDA reached EUR 854 million with a 23.90 percent margin, according to Quartr on October 1, 2026.

Cash generation also improved. Free cash flow before mergers and acquisitions reached EUR 91 million in the first half, an improvement of EUR 103 million from the prior-year period, while net leverage stood at 4.20 times, according to Quartr.

What changed in October?

The recent analyst signal was more cautious. Wall Street Zen lowered its rating from Buy to Hold in a note dated October 10, 2026, while MarketBeat reported a consensus rating of Reduce and an average price target of USD 10.00, both based on its October 10 report, according to MarketBeat.

Three dated milestones

On May 7, 2026, Grifols reported first-quarter revenue of EUR 1.70 billion and net profit of EUR 73 million. On July 28, 2026, first-half revenue reached EUR 3.574 billion and net profit EUR 227 million. On October 10, 2026, Wall Street Zen moved its rating from Buy to Hold, as reported by MarketBeat.

Upcoming reporting date

The next listed earnings date is November 10, 2026, according to TradingView.

Stock price and investor context

For investors, the central contrast is clear: Grifols delivered a 28.70 percent increase in first-half net profit while revenue growth was 2.60 percent at constant currency. The October rating change puts greater weight on whether cash flow and leverage continue to improve.

The stock was trading at EUR 10.13 at Lang & Schwarz on October 16, 2026, at 10:05 a.m. CEST. The further course of trading is shown by the continuously updated real-time quote of Grifols stock.